An iso-osmolar oral supplement increases natriuresis and does not increase stomal output in patients with an ileostomy: A randomised, double-blinded, active comparator, crossover intervention study.

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

This study aimed to compare how an iso-osmolar and a hyperosmolar oral supplement affect ileostomy output, urine production, and natriuresis as proxy measurements of water-electrolyte balance.

Why It Was Studied

Patients with an ileostomy often experience fluid and electrolyte depletion because of gastrointestinal loss.

Who Took Part

In a randomised, double-blinded, active comparator, crossover intervention study, the researchers included eight adult ileostomy patients who were independent of parenteral support.

Each period started with 24-hour baseline measurements, and the supplements were ingested during the following 48 h.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

Each person switched between Copper (Supplement) and the comparison at some point, usually with a gap in between.

All measurements were repeated in the last 24 h.

What Was Measured

Patients with an ileostomy often experience fluid and electrolyte depletion because of gastrointestinal loss.

Topics PubMed links to this paper include Electrolytes, Fluid Therapy, Ileostomy, Natriuresis, Osmolar Concentration, Solutions and Water-Electrolyte Balance.

The authors tagged it with the keywords Dehydration, Osmolality and Short bowel syndrome.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Copper (Supplement).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Copper (Supplement) compound page, all human trials.